Slingshot members are tracking this event:

Exelixis (EXEL) Presents Phase 2 CABOSUN Results Analyzing Cabozantinib Versus Pfizer's (PFE) Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 10, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Cabosun, Cabozantinib, Sunitinib, Previously Untreated, Advanced Renal Cell Carcinoma